Vertex Pharmaceuticals (VRTX) closed at $435.65 in the latest trading session, marking a -1.37% move from the prior day. This change lagged the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.36%.
Shares of the drugmaker witnessed a loss of 2.19% over the previous month, trailing the performance of the Medical sector with its loss of 1.19%, and the S&P 500's gain of 5.98%.
Analysts and investors alike will be keeping a close eye on the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to go public on May 4, 2026. In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.38 per share. This would mark year-over-year growth of 7.88%. Our most recent consensus estimate is calling for quarterly revenue of $3.01 billion, up 8.83% from the year-ago period.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $19.11 per share and revenue of $12.96 billion. These results would represent year-over-year changes of +3.86% and +8.03%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.44% lower within the past month. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 23.12. For comparison, its industry has an average Forward P/E of 21.43, which means Vertex Pharmaceuticals is trading at a premium to the group.
Investors should also note that VRTX has a PEG ratio of 1.67 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.6.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 89, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).